Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.10B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.76M
Average 1.66M
XERS Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Xeris Biopharma Holdings, Inc.NASDAQ: XERS
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q1 FY2026 net change in cash was $708K, compared with -$13.18M a year earlier. Trailing-twelve-month net change in cash was $53.21M. Over 3 fiscal years it compounded at -12.7% a year.
Context
- Net change in cash amounted to 13.5% of revenue in FY2025, up 11.5 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near $708K or moves back toward the trailing-twelve-month quarterly average of $13.3M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 39.32M USD
- Year-over-year change
- +866.1%
- 4-year CAGR
- -9.7%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.32M | +866.1% |
| FY2024 | 2024-12-31 | 4.07M | +107.4% |
| FY2023 | 2023-12-31 | (54.64M) | -192.5% |
| FY2022 | 2022-12-31 | 59.04M | +0.0% |
| FY2021 | 2021-12-31 | 59.04M | — |
Net Change in Cash vs competitors
How XERS compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1322.6% is the highest of 9, against a peer median of +117.9%.
- Net change in cash amounts to 16.9% of revenue for XERS, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €400.42M EUR | +563.3% | — | 33.1% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $152.87M USD | -166.0% | — | 158.8% |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $61.23M USD | -167.8% | +31.0% | — |
| LTM Mar 2026 | $53.21M USD | +1322.6% | -12.7% | 16.9% | |
| LTM Mar 2026 | $28.5M USD | +151.3% | — | — | |
| LTM Jun 2026 | $8.29M USD | +132.1% | -14.0% | 1.0% | |
| LTM Mar 2026 | $5.53M USD | +103.8% | — | 1.5% | |
| LTM Mar 2026 | $2.3M USD | -101.4% | — | — | |
| LTM Mar 2026 | $2.24M USD | +192.9% | +79.6% | 2.6% | |
| Peer median (excluding XERS) | — | +117.9% | +31.0% | 2.6% | |
Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (122.73M) | (94.66M) | (62.26M) | (54.84M) | 554K |
| Depreciation & Amortization | 1.88M | 12.67M | 13.16M | 12.63M | 12.16M |
| Deferred Income Tax | (1.42M) | (1.42M) | (1.25M) | (2.27M) | 0 |
| Stock-Based Compensation | 11.38M | 12.16M | 10.72M | 18.36M | 22.37M |
| Change in Working Capital | 11.85M | (35.15M) | (6.29M) | (8.82M) | (10.36M) |
| Accounts Receivables | (13.37M) | (13.37M) | (8.37M) | (1.22M) | (10.64M) |
| Inventory | (7.47M) | (7.47M) | (14.8M) | (8.78M) | (19.29M) |
| Accounts Payables | (4.32M) | (4.32M) | 6.96M | (9.61M) | (69K) |
| Other Working Capital | 19.98M | (9.99M) | 9.92M | 10.79M | 19.63M |
| Other Non-Cash Items | 3.5M | 3.52M | (1.1M) | (2.05M) | 3.91M |
| Operating Cash Flow | (102.89M) | (102.89M) | (47.02M) | (36.98M) | 28.63M |
| Capital Expenditures | (524K) | (524K) | (2.26M) | (868K) | (696K) |
| Acquisitions (Net) | 38.47M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (43.02M) | 0 | (43.74M) | (34.49M) | 0 |
| Sales of Investments | 34.99M | 34.99M | 40M | 40.24M | 0 |
| Other Investing Activities | 4.55M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 34.46M | 34.46M | (6M) | 4.88M | (696K) |
| Debt Repayment | 0 | 102.72M | 0 | 38.17M | 9.17M |
| Common Stock Issued | 27M | 30M | 581K | 0 | 13.1M |
| Common Stock Repurchased | (534K) | (468K) | (1.01M) | (3.73M) | (10.88M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.78M) | (604K) | 1.73M | 0 |
| Financing Cash Flow | 27.25M | 127.47M | (1.61M) | 36.17M | 11.39M |
| Effect of Forex Changes | (3K) | (4.35M) | 0 | 0 | 0 |
| Net Change in Cash | 59.04M | 59.04M | (54.64M) | 4.07M | 39.32M |
| Free Cash Flow | (103.42M) | (103.42M) | (49.29M) | (37.85M) | 27.93M |
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.